The high resistance of bacteria to clindamycin and cefepime: a call to revisit antibiotics reserved for use at tertiary hospitals in Tanzania

Wigilya P. Mikomangwa (✉ wpad.miko@gmail.com)

Muhimbili University of Health and Allied Sciences

George M. Bwire

Muhimbili University of Health and Allied Sciences

Manase Kilonzi

Muhimbili University of Health and Allied Sciences

Hamu Mlyuka

Muhimbili University of Health and Allied Sciences

Ritah Mutagonda

Muhimbili University of Health and Allied Sciences

Wema Kibanga

Muhimbili University of Health and Allied Sciences

Alphonse Ignace Marealle

Muhimbili University of Health and Allied Sciences

Omary Minzi

Muhimbili University of Health and Allied Sciences

Kennedy D. Mwambete

Muhimbili University of Health and Allied Sciences

Research

Keywords: Antibiotic resistance, clindamycin, cefepime, meropenem, reserved antibiotics, bacteria, susceptibility pattern

Posted Date: January 2nd, 2020

DOI: <https://doi.org/10.21203/rs.2.19863/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background Antibiotic resistance poses burden to the community and health care services. Efforts are being made at local, national and global level to combat the rise of antibiotic resistance including antibiotic stewardship. Surveillance to antibiotic resistance is of importance to aid in planning and implementing infection prevention and control measures. The study was conducted to assess the resistance pattern to cefepime, clindamycin and meropenem, which are reserved antibiotics for use at tertiary hospitals in Tanzania

Methods A Hospital-based antibiotic resistance surveillance was conducted between July and November 2019 using 201 consecutively selected clinical isolates at Muhimbili National Hospital and Bugando Medical Center, Tanzania. All organisms isolated were identified based on colony morphology, Gram staining and relevant biochemical tests. Antibiotic susceptibility testing was performed on Muller-Hinton agar using Kirby-Bauer disc diffusion method. Antibiotic susceptibility on the selected antibiotic discs (cefepime, clindamycin and meropenem) was performed according to the protocol by National Committee for Clinical Laboratory Standards.

Results A total of 201 clinical samples were tested in this study. Urine (39.8%, n=80) and blood (35.3%, n=71) accounted for most of the collected samples followed by pus (16.9%, n=34). The overall bacterial resistance to clindamycin, cefepime and meropenem was 70.1%, 72.4% and 8.5% respectively. Most (88.9%) of *Enterococcus* spp were resistant to clindamycin. About 68.4% *Staphylococcus aureus* isolates were resistant to clindamycin whereby 56.3%, 75.6%, 93.8% and 100% of the tested *Escherichia coli*, *Klebsiella* spp, *Pseudomonas aeruginosa* and *Enterobacter cloacae* respectively, were cefepime resistant. About 8.5% of isolated *Klebsiella* spp were resistant and 6.4% had intermediate susceptibility to meropenem. Also, *Pseudomonas aeruginosa* was resistant by 31.2% and 25% had intermediate susceptibility to meropenem. All *Acinetobacter baumannii* and *Proteus* spp (both 100.0%, n=4) were susceptible to meropenem.

Conclusion The overall bacterial resistance to clindamycin and cefepime is high and low in meropenem. Henceforth, culture and susceptibility results should be used to guide the use of these antibiotics. Antibiotics with low resistance rate should be introduced to the reserve category and continuous antibiotic surveillance is warranted.

Background

Antibiotic resistance is rising to a dangerous level and is a global concern; bacteria are adapting new resistance mechanisms and spreading them across the species and geographical location, thus threatening over-decade achievement to treat common infectious diseases (1,2). Antibiotic resistance is associated with prolonged length of hospital stay, increased treatment cost, morbidity and mortality (1,3,4). Recent data shows that, worldwide, more than 700,000 people die annually because of resistant superbugs and the trend is expected to reach 10 million deaths per annum in 2050 (5). In the USA, more

than 2.8 million people were infected by severe antibiotic resistant infections, and more than 35000 die from these infections every year (6). The problem is even worse in developing countries. For instance, in 2012, approximately 19400 and 56500 neonates in Nigeria and India respectively died from severe antibiotic-resistant pathogens (3). Also, antibiotics resistance has immense negative effect on the economy. It is estimated that, by 2030 if it is left unaddressed the world will incur annual cost of about 1 trillion US\$ (7).

In 2017, the World Health Organization (WHO) published the list of most evolving bacteria which are the leading the cause of health care facility acquired infection worldwide and pose great threat to the public health in general; *Enterococcus* spp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Escherichia coli*, collectively termed ESKAPE (3).

A growing list of infections such as urinary tract infections, pneumonia, bloodstream infections, reproductive tract infections, and foodborne diseases are becoming harder, and sometimes impossible to treat as antibiotics become less effective (1,2,8). Where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse (3,9). Similarly, in countries without standard treatment guidelines, antibiotics are often overprescribed by health workers and veterinarians and over-used by the public. In addition, over prescription of antibiotics has been mentioned to be the significant contributor of antibiotic resistance (10).

In 2019 the WHO established a model list of essential medicines in which antibiotics are included (11). The categories establish the antibiotics to be prescribed at different levels of health care facilities; access group (dispensaries, health centers), watch group (council hospitals) and reserved group (tertiary hospitals such as national, zonal, and specialized hospitals) (11). The reserved antibiotics play as the last weapon when all other antibiotics have failed. Grouping of antibiotics in respective categories is country specific. The Tanzanian Ministry responsible for health implemented the recommendations through the National Essential Medicine List (NEMLit) (12). The Ministry has created the reserve group that consists of cefepime, clindamycin and meropenem.

Several studies have reported the failure of clindamycin, cefepime and meropenem in different parts of the world (3,4,13). For example, in Africa 70% of *E. coli* and 77% of *K. pneumoniae* from clinical isolates were resistant to third generation cephalosporin. Invasive isolate from Europe indicated about 8% of *K. pneumoniae*, 19% of *P. aeruginosa* and 56% of *A. baumannii* isolated from blood and cerebral spinal fluid were resistant to carbapenem. In 2009, Mshana et al, reported inducible resistance to occur in MRSA isolated at Bugando Medical Center (BMC), Tanzania; about 61% (16/26) of MRSA exhibited inducible clindamycin resistance (14). Tanzania has also reported resistance to meropenem from clinical isolates particular *Pseudomonas* spp (15). Since categorizing of clindamycin, cefepime and meropenem in 2017 to reserve group, information on the susceptibility profile is scarce. Therefore, regular surveillance on the resistance profile of antibiotics is required to plan and implement infection prevention and control measures.

Methods

The study was conducted in two tertiary teaching hospitals namely Muhimbili National Hospital (MNH) and Bugando Medical Center (BMC) located at Dar es Salaam and Mwanza regions in Tanzania. MNH is a National Referral Hospital and University Teaching Hospital with 1,500-bed facility, attending 1,000 to 1,200 outpatients per week, admitting 1,000 to 1,200 inpatients per week. The diagnostic laboratory department at MNH is the leading diagnostic laboratory in Tanzania. Bugando Medical Centre (BMC) representing Zonal hospital has 950-bed capacity, serves a population of about 16 million people and attends around 300,000 patients each year. Both MNH and BMC clinical microbiology laboratories are accredited with the international standard ISO 15189:2007. The study was conducted between July and November 2019. A total of 201 consecutively selected clinical isolates were studied for susceptibility with special focus to clindamycin, meropenem and cefepime. Apart from assessing the susceptibility pattern of the three antibiotics, the socio-demographic and clinical information on the microbiological request form were documented on the case report form (CRF).

Laboratory Procedures

Gram stain, culture and identification

This was performed at the respective hospital (MNH & BMC) where organism from the clinical samples was isolated, cultured and identified according to their laboratory protocol. Direct Gram stain films were performed to examine the presence of microorganisms in the sample. Depending on the nature of the sample (throat swab, urine, stool, blood or sputum) microbiological culture was performed using appropriate culture media and conditions as per microbiology laboratory protocol. All organisms isolated were identified based on colony morphology, Gram staining and relevant biochemical tests (16,17).

Antibiotic susceptibility testing

Antibiotic susceptibility testing was performed on Muller-Hinton agar using Kirby-Bauer disc diffusion method at BMC and MNH clinical microbiology laboratory. Antibiotic susceptibility on the selected antibiotic discs; cefepime (30µg), clindamycin (2µg) and meropenem (10µg), was performed according to the protocol by Clinical and Laboratory Standards (CLSI) (18).

Interpretation and Reporting of the Results

Using the published CLSI guidelines, the susceptibility or resistance of the organism to each drug tested was determined (18). For each drug, the zone size was indicated on the recording sheet as susceptible (S), intermediate (I), or resistant (R) based on the interpretation chart (16).

Quality Control

The American Type Culture Collection (ATCC) standard bacteria corresponding to each

clinical isolate was used as control microorganisms for instance (18).

Data analysis

The collected microbiological information, socio-demographic and clinical data were extracted from the CRF to Microsoft excel, coded and analyzed using Statistical Package for Social Sciences (SPSS) version 23. The frequency distribution and proportion of identified bacteria per type of sample collected were summarized. The proportion of resistant bacteria per antibiotic (clindamycin, cefepime and meropenem) was determined. Patients' age (in years) was categorized as ≤ 12 (children) and >12 (adult) as per MNH and BMC admission criteria. The differences in proportion of categorical variables were compared by Fisher's exact or Pearson's Chi-Square test. The two tailed p-value of less than 0.05 was considered statistically significant.

Results

Socio-demographic and clinical information

Overall 51.4% were male patients with age above 12years old (57.9%). More than 20% of patients had fever, 6.6% had infected wound (either injury, at incision site or abdomen burst post-surgery) abdominal pain and difficulty in breathing (both 3.8%), dysuria, cough and cardiac diseases (each 3.3%). Also, anemia, sepsis and vomiting (each 2.7%) were reported (Table 1).

Type of samples used and culture results

A total of 201 clinical samples was involved in this study. Urine (39.8%, n=80) and blood (35.3%, n=71) accounted for most of the collected samples followed by pus (16.9%, n=34). Most of the blood samples were collected from children (46.8%) than adults (27.4%) (p-value<0.001). High proportion of pus (22.6%) and sputum (9.4%) samples were collected from adults while 48.1% of urine sample were collected from children (p-value<0.001). The one throat swab sample was collected from a child.

Most (64.2%) of clinical isolates were found to be Gram negative strains. The distribution of type of strain (Gram negative or positive) did not differ by age groups (p-value=0.88). The most identified bacteria were *S. aureus* (28.4%), *Klebsiella spp* (23.4%), followed by *Escherichia coli* (17.9%). *Staphylococcus aureus* (56.3%) was the leading bacteria isolated from blood followed by *Klebsiella spp* (22.5%) while *E. coli* was highly (32.5%) found in urine samples. The highest proportion (38.5%) of *Pseudomonas aeruginosa* was found in sputum samples (Table 2).

Resistance patterns of the tested bacteria

Resistance to clindamycin

The Gram positive pathogens tested for susceptibility were *Enterococcus Spp*, *S. aureus* and *Streptococcus pyogen*. The overall proportion Gram positive pathogens resistant to clindamycin was 70.1% (Figure 1). Whereby 88.9% (n=9) of *Enterococcus Spp* and 68.4% (n=57) of *S. aureus* were resistant to clindamycin.

Resistance to cefepime

The total of 132 bacterial isolates were subjected to susceptibility test against cefepime. The overall proportion of Gram negative bacteria resistant to cefepime was 72.4% (Figure 1). Only 15.4% of isolates were susceptible to cefepime. Of 45 *Klebsiella spp* were tested for susceptibility to cefepime, 75.6% were resistant and only 11.1% were susceptible. Whereas, 32 isolates of *E. coli* tested for susceptibility to cefepime; 56.3% were resistant and 21.9% were susceptible. Also, sixteen (16) *P. aeruginosa* isolated were tested for susceptibility to cefepime of which 93.8% were found to be resistant. Fourteen (14) *Citrobacter spp*, were tested by which 85.7% (n=14) were resistant. We found that, all five *Enterobacter cloacae* tested (100%) were resistant. Only four (4) *A. baumannii* were isolated and tested for susceptibility to cefepime, 3 (75%) of which were resistant (Table 3).

Resistance to meropenem

Furthermore, the Gram negative bacteria (n=128) isolated from clinical samples were tested for susceptibility against meropenem. Most of the pathogens were meropenem susceptible (85.3%), however, 8.5% of pathogens were found resistant (Figure 1). The isolated *Klebsiella spp* (n=47) were tested for susceptibility to meropenem, of which 8.5% were resistant and 6.4% had intermediate susceptibility; one *K. oxytoca* and two *K. pneumonia* were resistant. Of n=16 *P. aeruginosa* isolated 31.2% were resistant and 25% had intermediate susceptibility. All *A. baumannii* and *Proteus spp* (both 100.0%, n=4) were susceptible to meropenem (Table 3)

Discussion

This study describes the resistance profile of clindamycin (lincosamide), cefepime (fourth generation cephalosporin) and meropenem (carbapenem). In 2017 these antibiotics were reserved for use at tertiary hospitals following the WHO recommendation as a key focus to antibiotic stewardship (12,19). The study found the overall resistance to clindamycin, cefipime and meropenem to be 70.1%, 72.4% and 8.5% respectively, which was higher than previous studies conducted in Tanzania (14,15,20).

The study also found resistant pathogenic bacteria in the collected samples as previously reported by Nyambura et al, who did the study at BMC (20). Sadly, most of the blood samples collected in this study had resistant *S. aureus* which was suggestive of bloodstream infection as evidenced by more than 18% of patients who had fever. It has been documented that, *S. aureus* was the leading cause of blood stream infection acquired in hospital settings (21–23). *S. aureus* get access to blood through intravascular devices such as central venous catheters, peripheral intravenous catheters, arterial catheters and urinary catheter (21,22). Thus presence of such microorganisms that are introduced through invasive procedures

such as incision, intubation, puncture, and drug injections could greatly contribute to long hospital stays as results of bacteremia(21). Bloodstream infection have been reported to be more common among children similar to our study (22,23).

Bloodstream infection is associated with high mortality rate, morbidity and prolonged hospital stay making the treatment more complicated in face of increased resistant *S. aureus* (21,24). Our study found 68.4% of tested *S.aureus* were resistant similar to Mshana et al, study in 2009 that found 61% of MRSA were resistant to clindamycin (14). Clindamycin is one of the potential alternative in high prevalent MRSA infections (25). The observed increased proportion of resistance could suggest extensive use of the antibiotic that leads to increase in resistance with time (26). In this study, *Enterococcus* spp isolates were found in urine and blood samples thus posing risk for development of urinary tract and bloodstream infections respectively similar to what has been reported previously(20). Most (88.9%) of the *Enterococcus* spp were resistant to clindamycin similar to the study by Azin et al who found the 96% resistance to clindamycin in Iran (27). It has been documented that the *Enterococci* are intrinsically resistant to clindamycin, which could explain the observed resistant pattern (8,28). Being normal flora of the gastrointestinal tract with frequent contact to antibiotics which are, in high rate misused, could increase the proportion of resistant *Enterococci*(9,29,30). Also, the previous use of clindamycin as additive drug to quinine for treatment of uncomplicated malaria in pregnant could have accelerated the resistance of this antibiotic (31).

Most of the Gram negative pathogens in this study were resistant to cefipime which is the fourth cephalosporin generation antibiotic for instance, 75.6% *Klebsiella* Spp, 93.8% *P. aeruginosa*, 75.0% *A.baumannii*, and 56.3% *E.coli* were resistant. This pattern of resistance is comparable to the previous study that was conducted at BMC, the proportion of resistant Gram negative bacteria was 80.6%, 87.5% and 63.2% in the order of *Klebsiella* spp, *Paeruginosa*, 56.3% *E.coli* (20). The slight observed difference in proportion could be attributed to the difference in generations of cephalosporin used. Their study assessed the susceptibility of Gram negative bacteria using third generation cephalosporin (ceftriaxone/cefotaxime)(20), contrary to our study in which we used fourth generation cephalosporin (cefepime). Indeed, the observed high proportion of resistant bacteria was almost similar to the overall proportion of resistant Gram negative bacteria to third generation cephalosporin in Africa (3). These bacteria are among the most mutating bacteria with high risk to human health (1,32). The high proportion of resistant Gram negative bacteria to fourth generation cephalosporin (cefepime) could be suggestive of bacteria adaptive mechanisms by cross-resistance between generations of the same antibiotic class (32). The overuse and irrational use of antibiotics especially third generation cephalosporin (ceftriaxone) could contribute to failure of subsequent cephalosporin generations (29,30,33).

Pseudomonas aeruginosa and *Klebsiella* spp were isolated in all samples, this could have contributed to bloodstream infection, wound infection, urinary tract and respiratory tract infections as previously described. About 31.2% of the tested *P. aeruginosa* isolates were meropenem resistant contrary to the study by Sabrina et al who reported 8.9% of resistant *Pseudomonas aeruginosa*. Their study was conducted between 2010–2011, more than eight years ago. The trend of increasing resistant

P.aeruginosa was noted in a study that evaluated clinical isolated at BMC from 2007 to 2012 that found the prevalence of resistant *P.aeruginosa* to be 19.5% (15). A systematic review on antibiotic resistance in Africa found *P.aeruginosa* to be one of the bacteria resistant to carbapenem (34). The trend of increasing bacteria strains resistant to meropenem is threatening since this drug serve as the last weapon for most of Gram negative bacteria resistant to the commonly used antibiotics.

Furthermore, we found meropenem resistant *Klebsiella* spp to be 8.5% which was higher than the previous study by Martha et al (1.5%) who conducted the study at BMC (15). The increase in proportion of resistant *P. aeruginosa* and *Klebsiella* Spp could indicate heightening of antibiotic resistance with time necessitating questioning the effectiveness of the control measures in place. High susceptibility observed to some of pathogenic bacteria such as *A.baumannii* and *Proteus* spp could indicate good performance in some bacteria though the increasing resistance to some highly mutating bacteria is warranting strict control measures. Carbapenems are considered the treatment of choice and last option for the common nosocomial infection caused by *P. aeruginosa* resistant to other β -lactam antibiotics (35). Inappropriate use of antibiotics such as carbapenems especially in private health facilities could increase the prevalence of resistant bacteria to carbapenems; pressure from pharmaceutical companies and intending to make profit could be contributing factors (36–38) .

Limitations

This study is one of few studies conducted in East Africa that assessed the resistance pattern of clindamycin, cefepime and meropenem, however, most of the previous studies did not include cefepime which is the fourth generation cephalosporin and clindamycin(34,35), hence the current susceptibility pattern of these antibiotics has limited index comparator. Our study aimed at evaluating the current status of antibiotic resistance burden in our settings after the implementation of WHO stewardship program of reserving some antibiotics to be used as last resort when multidrug resistant infection is encountered. Therefore, we focused only to survey the resistant pattern of clindamycin, cefepime and meropenem. Being a cross-sectional design, the clinical outcomes of patients from which the resistant bacteria were isolated were not documented, therefore these findings should be interpreted with cautions because they don't equate to clinical outcomes. Furthermore, whether the infection was community or hospital acquired was not evaluated. The mechanisms of resistance and the molecular markers were not the scope of this study. In addition, this study was conducted at two tertiary teaching hospitals excluding other tertiary hospitals in the country hence should be generalized with high precaution.

Conclusion

High resistance to clindamycin and cefepime was revealed in this study. Meropenem resistant to *P. aeruginosa* and *Klebsiella* Spp was also observed. In addition, the pathogenic bacteria of high priority (ESKAPE) were resistant to all studied antibiotics at variable proportion. We recommend routine culture and susceptibility testing for proper use of these antibiotics as well as searching for new antibiotics. Since clindamycin and cefepime are becoming obsolete, the Ministry responsible for Health should

reconsider classifying these two antibiotics as reserve antibiotics. Taking into account that the resistance to antibiotics can assume uneven geographical distribution; either a national or zonal antibiotic resistance surveillance center should be established. The studied center (s) may serve as reference for monitoring the trend of antibiotic resistance as receive patients from different parts of the country and thus aid in planning and implementing control measures that may be stratified region.

Abbreviations

ESKAPE: *Enterococcus spp.*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Escherichia coli*, NEMLT: National Essential Medicine List, MRSA: methicillin resistant *Staphylococcus aureus*, BMC: Bugando Medical Center; MNH: Muhimbili National Hospital

Declarations

Ethics approval and consent to participate

Approval to conduct this study was sought from the Ethical Committee of Muhimbili University of Health and Allied Sciences. In addition, permission was requested from the appropriate authorities of MNH and BMC to conduct the study at their facilities.

Consent for publication

Not applicable

Availability of data and material

The dataset generated and/or analyzed during this study is available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This study was funded by the Swedish International Development Cooperation Agency-Sida through Muhimbili University of Health and Allied Sciences (MUHAS), through Sida-small grant program coordinated by the MUHAS Director of Research and Publication. The funder did not participate in the design, analysis, interpretation or manuscript preparation.

Authors' contributions

WPM, MK, GMB designed the study and coordinated data collection. WPM conducted data analysis and drafted the manuscript. GMB, MK conceptualized the study. WPM, MK, WK, HM, AIM, RM, OM, KM and GMB participated in, interpretation of data and manuscript development. All authors read and approved the final manuscript.

Acknowledgements

We highly appreciate the contribution from Nyanda Shango and his colleagues at BMC microbiology laboratory together with James Kalabashanga from MNH for their technical expertise during the phase of data collection.

Authors' information (optional)

¹*Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania*

²*Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied Sciences*

References

1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med*. 2004;10(12):S122–9.
2. Wormser GP, Bergman MM. The Antibiotic Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers, 2nd Edition By Stuart B. Levy Cambridge, Massachusetts: Perseus Publishing, 2002. 376 pp., illustrated. \$17.50 (paper). *Clin Infect Dis*. 2003 Jan 15;36(2):238.
3. Geneva. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. *World Heal Organ*. 2017;12.
4. Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: Report of the British society for antimicrobial chemotherapy/healthcare infection society/british infection association joint working party. *J Antimicrob Chemother*. 2018;73(March 2015):iii2–78.
5. Roope LSJ, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, et al. The challenge of antimicrobial resistance: What economics can contribute. *Science* (80-). 2019;364.
6. Frieden T. Antibiotic resistance threats in the United States. *Centers Dis Control Prev*. 2013;114.
7. Berthe, Franck Cesar Jean; Wadsworth, Jonathan; Thiebaud, Alessia; Marquez, Patricio V.; Baris E. Pulling Together to Beat Superbugs Knowledge and Implementation Gaps in Addressing Antimicrobial Resistance. HNP/Agriculture Glob Antimicrob Resist Initiat Washington, DC World Bank Gr. 2019;
8. Cardoso T, Ribeiro O, Aragão IC, Costa-Pereira A, Sarmento AE. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: A large cohort study. *BMC Infect*

Dis. 2012;12.

9. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. *Lancet* (London, England). 2016 Jan 9;387(10014):168–75.
10. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. *Crit Care*. 2017 Nov 14;21(1):276.
11. WHO. World health organization model list of essential medicines. *Ment Holist Heal Some Int Perspect*. 2019;119–34.
12. Ministry of Health and Social Welfare. Standard treatment guidelines & national essential medicines list, Tanzania mainland G. 2017. 47 p.
13. Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. *Lancet Infect Dis*. 2011;11(1):30–8.
14. Mshana SE, Kamugisha E, Mirambo M, Chalya P, Rambau P, Mahalu W. Prevalence of clindamycin inducible resistance among methicillin-resistant *Staphylococcus aureus* at Bugando Medical Centre , Mwanza , Tanzania. 2009;11(2):59–64.
15. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F. Carbapenemase Genes among Multidrug Resistant Gram Negative Clinical Isolates from a Tertiary Hospital in Mwanza , Tanzania. 2014;2014.
16. Collee, J.G., Miles, R.S. and Watt B. Tests for the Identification of Bacteria. In: Collee, J.G., Marmion, B.P, Fraser, A.G. and Simmons, A., Eds., Mackie & McCartney Practical Medical Microbiology. 14th Edition, Churchill Livingstone, New York; 1996. p. 131–51.
17. Şimşek S, Yurtseven N, Gerçekogalu H, Izgi F, Sohtorik Ü, Canik S, et al. Ventilator-associated pneumonias in a cardiothoracic surgery centre postoperative intensive care unit. *J Hosp Infect*. 2001 Apr 1;47(4):321–4.
18. M02-A12: Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition. 2015.
19. Organization WH. WHO Model List of Essential Medicines. World Heal Organ [Internet]. 2013; (October):1–43. Available from: http://www.who.int/medicines/organization/par/edl/expcom13/eml13_en.pdf
20. Moremi N, Claus H, Mshana SE. Antimicrobial resistance pattern : a report of microbiological cultures at a tertiary hospital in Tanzania. *BMC Infect Dis*. 2016;1–7.
21. Bartlett JG. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. *Infect Dis Clin Pract*. 2004;12(6):376.
22. Bai Y, Zheng Z, Du M, Yao H, Liu Y, Suo J. Bloodstream Infection and Its Clinical Characteristics and Relevant Factors Associated with Interventional Therapy in a Large Tertiary Hospital: A Six Years Surveillance Study. *Biomed Res Int*. 2019;2019.
23. Mhada T V, Fredrick F, Matee MI, Massawe A. Neonatal sepsis at Muhimbili National Hospital, Dar es Salaam, Tanzania; aetiology, antimicrobial sensitivity pattern and clinical outcome. *BMC Public*

- Health. 2012;12(1):904.
24. Karchmer AW. Nosocomial Bloodstream Infections: Organisms, Risk Factors, and Implications. Clin Infect Dis. 2000 Sep 1;31(Supplement_4):S139–43.
 25. Fokas S, Fokas S, Tsironi M, Kalkani M, Dionysopoulou M. Prevalence of inducible clindamycin resistance in macrolide-resistant *Staphylococcus* spp. Clin Microbiol Infect. 2005 Apr 1;11(4):337–40.
 26. Odsbu I, Khedkar S, Lind F, Khedkar U, Nerkar SS, Orsini N, et al. Trends in resistance to extended-spectrum cephalosporins and carbapenems among *Escherichia coli* and *Klebsiella* spp. Isolates in a district in Western India during 2004–2014. Int J Environ Res Public Health. 2018;15(1):1–15.
 27. Sattari-Maraji A, Jabalameli F, Node Farahani N, Beigverdi R, Emaneini M. Antimicrobial resistance pattern, virulence determinants and molecular analysis of *Enterococcus faecium* isolated from children infections in Iran. BMC Microbiol. 2019;19(1):156.
 28. Kristich CJ, Rice LB, Arias CA. Enterococcal Infection — Treatment and Antibiotic Resistance Molecular Mechanisms of Antibiotic Resistance in Enterococci. 2014;1–31.
 29. Sonda TB, Horumpende PG, Kumburu HH, van Zwetselaar M, Mshana SE, Alifrangis M, et al. Ceftriaxone use in a tertiary care hospital in Kilimanjaro, Tanzania: A need for a hospital antibiotic stewardship programme. PLoS One. 2019;14(8):1–11.
 30. Mboya EA, Sanga LA, Ngocho JS. Irrational use of antibiotics in the Moshi Municipality Northern Tanzania: A cross sectional study. Pan Afr Med J. 2018;31:1–10.
 31. Edition TUR of TSTG and EMLM of H and SWF. the United Republic of Tanzania Standard Treatment Guidelines and Essential Medicines List Ministry of Health and Social Welfare Fourth Edition. 2013. 42–43 p.
 32. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016;2016.
 33. Wangai FK, Masika MM, Lule GN, Karari EM, Maritim MC, Jaoko WG, et al. Bridging antimicrobial resistance knowledge gaps: The East African perspective on a global problem. PLoS One. 2019;14(2):1–12.
 34. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, et al. Antimicrobial resistance in Africa: A systematic review. BMC Infect Dis. 2017;17(1):1–17.
 35. Ssekatawa K, Byarugaba DK, Wampande E, Ejobi F. A systematic review: The current status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11(1):1–9.
 36. Yan K, Xue M, Ye D, Yang C, Chang J, Jiang M, et al. Antibiotic prescribing practices in secondary and tertiary hospitals in Shaanxi province, western China, 2013–2015. PLoS One. 2018;13(12):2013–5.
 37. Sharma M, Eriksson B, Marrone G, Dhaneria S, Lundborg CS. Antibiotic prescribing in two private sector hospitals; one teaching and one non-teaching: A cross-sectional study in Ujjain, India. BMC Infect Dis. 2012;12.

38. Landstedt K, Sharma A, Johansson F, Stålsby Lundborg C, Sharma M. Antibiotic prescriptions for inpatients having non-bacterial diagnosis at medicine departments of two private sector hospitals in Madhya Pradesh, India: a cross-sectional study. *BMJ Open*. 2017 Apr 1;7(4):e012974.

Tables

Table 1. Socio-demographic and clinical characteristics of patients from which the samples were collected.

Variable	Frequency	Percentage (%)
Patient category^a		
Children	77	38.3
Adult	106	52.7
Sex^a		
Male	94	46.8
Female	89	44.3
Place of residence^b		
Urban	76	37.8
Rural	18	9.0
Comorbidities/symptoms/signs[‡]		
abdominal pain	8	3.9
anemia	5	2.5
breast swelling	2	1.0
heart disease	8	3.9
chronic kidney disease	3	1.5
congenital pneumonia	2	1.0
convulsion	2	1.0
cough	7	3.5
diarrhea	4	2.0
difficulty in breathing	7	3.5
diabetes mellitus	2	1.0
dysuria	6	3.0
ear swelling	2	1.0
fever [‡]	37	18.4
hematuria	2	1.0
HIV	3	1.5
joint pain	3	1.5
sickle cell disease	3	1.5
sepsis	5	2.5
skin rash	2	1.0
TB	2	1.0
UTI	3	1.5
vomiting	5	2.5
wound infection	12	6.0
vaginal discharge	2	1.0
Others [‡]	13	6.5
undocumented [‡]	54	26.5

^aFew laboratory request form did not have information on age or sex (both n=18)

^bSome place of residence was not documented for some patients (n=107)

‡Most of the comorbidities were accompanied with fever, however, some were documented fever alone.

Abbreviations: TB, tuberculosis; UTI, urinary tract infection; HIV, human immunodeficiency virus.

⌘Undocumented comorbidities, signs or symptoms accounted for 26.5% (n=54)

⌘Others such as amenorrhea, burn, cloudy urine, eclampsia, chest pain, lower limb edema, lung cancer, malaria, nasal bleeding, nephritis, peritonitis, urethral itching, (each n=1)

Table 2. Bacterial isolates distribution by specimens

Identified bacteria	Blood: n=71 n(%)	Pus: n=34 n(%)	Sputum, n=13 n(%)	Urine: n=80 n(%)	Total ^{‡‡} n=201 n(%)
<i>Acinetobacter baumannii</i>	2 (2.8)	1 (2.9)	0 (0.0)	1 (1.3)	4 (2.0)
<i>Citrobacter spp</i> ^a	1 (1.4)	4 (11.8)	1 (7.7)	10 (12.5)	16 (8.0)
<i>Escherichia coli</i>	0 (0.0)	9 (26.5)	1 (7.7)	26 (32.5)	36 (17.9)
<i>Enterobacter cloacae</i>	3 (4.2)	0 (0.0)	0 (0.0)	2 (2.5)	5 (2.5)
<i>Enterococcus spp</i> ^b	4 (5.6)	1 (2.9)	0 (0.0)	9 (11.3)	14 (7.0)
<i>Klebsiella spp</i> ^c	16 (22.5)	6 (17.6)	3 (23.1)	22 (27.5)	47 (23.4)
<i>Pseudomonas aeruginosa</i>	5 (7.0)	3 (8.8)	5 (38.5)	3 (3.8)	16 (8.0)
<i>Proteus spp</i> ^d	0 (0.0)	3 (8.8)	0 (0.0)	1 (1.3)	4 (2.0)
<i>Staphylococcus aureus</i>	40 (56.3)	7 (20.6)	3 (23.1)	6 (7.5)	57 (28.4)
Other spp ^e	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.0)

^a*Citrobacter spp*; *Citrobacter freundii* (n=5), *Citrobacter koseri* (n=4), unidentified *Citrobacter Spp* (n=7)

^b*Enterococcus spp*; *Enterococcus faecalis* (n=1), *Enterococcus aerogenes* (n=5), unidentified *Enterococcus spp* (n=8).

^c*Klebsiella spp*; *Klebsiella oxytoca* (n=8), *Klebsiella pneumoniae* (n=26), unidentified *Klebsiella Spp* (n=13).

^d*Proteus spp*; *Proteus Mirabilis* (n=2), *Proteus vulgaris* (n=2).

^e*Streptococcus pyogen* (n=1) and *Shigella spp* (n=1) were isolated from throat swab and stool respectively.

‡‡Samples not included in the table (n=3); stool, throat swab and urethral swab (each n=1).

Table 3. Susceptibility pattern of tested bacteria to cefepime, meropenem and clindamycin

Bacteria	Cefepime n(%)			Meropenem, n(%)			Clindamycin n(%)		
	S	I	R	S	I	R	S	I	R
<i>Enterobacter aerogenes</i>	1 (25.0)	0 (0.0)	3 (75.0)	4 (100.0)	0 (0.0)	0 (0.0)	NA	NA	NA
<i>Enterobacter spp</i>	2 (12.5)	2 (12.5)	12 (75.0)	15 (93.8)	0 (0.0)	1 (6.3)	NA	NA	NA
<i>Escherichia coli</i>	7 (21.9)	7 (21.9)	18 (56.3)	35 (97.2)	0 (0.0)	1 (2.8)	NA	NA	NA
<i>Enterobacter cloacae</i>	0 (0.0)	0 (0.0)	5 (100.0)	4 (80.0)	1 (20.0)	0 (0.0)	NA	NA	NA
<i>Staphylococcus spp</i>	1 (20.0)	0 (0.0)	4 (80.0)	5 (100.0)	0 (0.0)	0 (0.0)	1 (11.1)	0	8 (88.9)
<i>Shigella spp</i>	5 (11.1)	6 (13.3)	34 (75.6)	40 (85.1)	3 (6.4)	4 (8.5)	NA	NA	NA
<i>Salmonella</i>	1 (6.3)	0 (0.0)	15 (93.8)	7 (43.8)	4 (25.0)	5 (31.3)	NA	NA	NA
<i>Streptococcus spp</i>	2 (50.0)	0 (0.0)	2 (50.0)	4 (100.0)	0 (0.0)	0 (0.0)	17 (29.8)	1 (1.8)	39 (68.4)
<i>Streptococcus</i>	0 (0.0)	0 (0.0)	4 (100.0)	2 (50.0)	0	2 (50.0)	NA	NA	NA
<i>Staphylococcus aureus</i>	1 (100.0)	0 (0.0)	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	NA	NA	NA
<i>Staphylococcus aureus</i>	NA	NA	NA	NA	NA	NA	0 (0.0)	1 (100.0)	0 (0.0)

Abbreviations: S, susceptible; I, intermediate; R, resistant; spp, species, NA, isolated bacteria were not tested on the respective antibiotic

Figures

Figure 1

Proportion of pathogens resistant to cefepime, meropenem and clindamycin